A novel promising therapy for vein graft restenosis: Overexpressed Nogo-B induces vascular smooth muscle cell apoptosis by activation of the JNK/p38 MAPK signaling pathway

Medical Hypotheses

Volumn 77, Issue 2, 2011, Pages 278-281

  Zheng, Hui ^a   Xue, Song ^a   Lian, Feng ^a   Wang, Yong yi ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN NOGO; PROTEIN NOGO B; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; NONHUMAN; PATHOGENESIS; RESTENOSIS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VEIN GRAFT RESTENOSIS;

APOPTOSIS; CORONARY ARTERY BYPASS; ENZYME ACTIVATION; GENE THERAPY; GRAFT OCCLUSION, VASCULAR; HUMANS; MAP KINASE KINASE 4; MODELS, BIOLOGICAL; MYELIN PROTEINS; MYOCYTES, SMOOTH MUSCLE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 79960621201     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.04.035     Document Type: Article

References (34)

1. Shuhaiber J.H., Evans A.N., Massad M.G., Geha A.S. Mechanisms and the future directions for prevention of vein graft failure in coronary bypass surgery. Eur J Cardio ThoracSurg 2002, 22:387-389.
2. Shah P.J., Gordon I., Fuller J., Seevanayagam S., Rosalion A., Tatoulis J. Factors affection saphenous vein graft patency: clinical and angiography study in 1402 symptomatic patients operated on between 1977 and 1999. J Thorac Cardiovasc Surg 2003, 126(6):1972-1977.
3. Grip L., Albertsson P., Schersten F. Survival benefits of CABG and PCI-facts and speculations [J]. Scand Cardiovasc J 2004, 38(1):3-6.
4. Mangano D.T. Aspirin and mortality from coronary bypass surgery [J]. N Engl J Med 2002, 347(17):1309-1317.
5. Porter K.E., Turner N.A. Statins for the prevention of vein graft stenosis: a role for inhibition of matrix metalloproteinase-9. Biochem Soc Trans 2002, 30(2):120-126.
6. Knatterud G.L., Rosenberg Y., Campeau L., et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG investigators. Circulation 2000, 102(2):157-165.
7. Acevedo L., Yu J., Erdjument-Bromage H., et al. A new role for Nogo as a regulator of vascular remodeling. Nat Med 2004, 10(4):382-388.
8. Paszkowiak J.J., Maloney S.P., Kudo F.A., et al. Evidence supporting changes in Nogo-B levels as a marker of neointimal expansion but not adaptive arterial remodeling. Vascul pharmacol 2007, 46(4):293-301.
9. Mitra A.K., Gangahar D.M., Agrawal D.K. Cellular, molecular and immunological mechanisms in the pathophysiology of vein graft intimal hyperplasia. Immunol Cell Biol 2006, 84(2):115-124.
10. Kockx M.M., Knaapen M.W. The role of apoptosis in vascular disease. J Pathol 2000, 190:267-280.
11. Schachner T., Oberhuber A., Zou Y., et al. Rapamycin treatment is associated with an increased apoptosis rate in experimental vein grafts. Eur J Cardiothorac Surg 2005, 27(2):302-306.
12. Mayr M., Li C., Zou Y., Huemer U., Hu Y., Xu Q. Biomechanical stress-induced apoptosis in vein grafts involves p38 mitogen-activated protein kinases. FASEB J 2000, 14(2):261-270.
13. Kamenz J., Seibold W., Wohlfrom M., et al. Incidence of intimal proliferation and apoptosis following balloon angioplasty in an atherosclerotic rabbit model. Cardiovasc Res 2000, 45(3):766-776.
14. Frischknecht K., Greutert H., Weisshaupt C., et al. Different vascular smooth muscle cell apoptosis in the human internal mammary artery and the saphenous vein. Implications for bypass graft disease. J Vasc Res 2006, 43(4):338-346.
15. George S.J., Angelini G.D., Capogrossi M.C., Baker A.H. Wild-type p53 gene transfer inhibits neointima formation in human saphenous vein by modulation of smooth muscle cell migration and induction of apoptosis. Gene Ther 2001, 8(9):668-676.
16. Wan S., George S.J., Nicklin S.A., Yim A.P., Baker A.H. Overexpression of p53 increases lumen size and blocks neointima formation in porcine interposition vein grafts. Mol Ther 2004, 9(5):689-698.
17. George S.J., Lloyd C.T., Angelini G.D., Newby A.C., Baker A.H. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 2000, 101(3):296-304.
18. Chang L., Karin M. Mammalian MAP kinase signalling cascades. Nature 2001, 410(6824):37-40.
19. Widmann C., Gibson S., Jarpe M.D., Johnson G.L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 1999, 79(1):143-180.
20. Ichijo H. From receptors to stress-activated MAP kinases. Oncogene 1999, 18(45):6087-6093.
21. Shen Y.H., Godlewski J., Zhu J., et al. Cross-talk between JNK/SAPK and ERK/MAPK pathways: sustained activation of JNK blocks ERK activation by mitogenic factors. J Biol Chem 2003, 278(29):26715-26721.
22. Cross T.G., Scheel-Toellner D., Henriquez N.V., Deacon E., Salmon M., Lord J.M. Serine/threonine protein kinases and apoptosis. Exp Cell Res 2000, 256(1):34-41.
23. Sotoudeh M., Li Y.S., Yajima N., et al. Induction of apoptosis in vascular smooth muscle cells by mechanical stretch. Am J Physiol 2002, 282(5):H1709-16.
24. Mayr M., Hu Y., Hainaut P., Xu Q. Mechanical stress-induced DNA damage and rac-p38 MAPK signal pathways mediate p53-dependent apoptosis in vascular smooth muscle cells. FASEB J 2002, 16(11):1423-1425.
25. Han Y., Wu G., Deng J., et al. Cellular repressor of E1A-stimulated genes inhibits human vascular smooth muscle cell apoptosis via blocking P38/JNK MAP kinase activation. J Mol Cell Cardiol 2010, 48(6):1225-1235.
26. Tsujimoto A., Takemura G., Mikami A., et al. A therapeutic dose of the lipophilic statin pitavastatin enhances oxidant-induced apoptosis in human vascular smooth muscle cells. J Cardiovasc Pharmacol 2006, 48(4):160-165.
27. Oertle T., Huber C., van der Putten H., Schwab M.E. Genomic structure and functional characterisation of the promoters of human and mouse Nogo/rtn4. J Mol Biol 2003, 325(2):229-323.
28. Li Q., Qi B., Oka K., et al. Link of a new type of apoptosis-inducing gene ASY/Nogo-B to human cancer. Oncogene 2001, 20(30):3929-3936.
29. Tagami S., Eguchi Y., Kinoshita M., et al. A novel protein, RTN-XS, interacts with both Bcl-XL and Bcl-2 on endoplasmic reticulum and reduces their anti-apoptotic activity. Oncogene 2000, 19(50):5736-5746.
30. Watari A., Yutsudo M. Multi-functional gene ASY/Nogo/RTN-X/RTN4: apoptosis, tumor suppression, and inhibition of neuronal regeneration. Apoptosis 2003, 8(1):5-9.
31. Oertle T., Merkler D., Schwab M.E. Do cancer cells die because of Nogo-B?. Oncogene 2003, 22(9):1390-1399.
32. Rousseau S., Peggie M., Campbell D.G., et al. Nogo-B is a new physiological substrate for MAPKAP-K2. Biochem J 2005, 391(Pt 2):433-440.
33. Rousseau S., Dolado I., Beardmore V., et al. CXCL12 and C5a trigger cell migration via a PAK1/2-p38alpha MAPK-MAPKAP-K2-HSP27 pathway. Cell Signal 2006, 18(11):1897-1905.
34. Trono D. Lentiviral Vectors 2002, Springer-Verlag, New York/Berlin/Heidelberg.